#### Substitute for form 1449A/PTO (modified)

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

e as many sheets as necessary)

Page 1 of 4

Application Number	10/624,419
Filing Date	July 22, 2003
First Named Inventor	Michael J. Rice
Art Unit	
Examiner Name	Unknown
Attorney Case Number	54563US011

			U.S. Patent	Documents	
Exam. Init.*	Cite No.	Document Number  Doc. Number-(Kind Code if Known)	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SVH	A1	US- 3,314,941	04-18-1967	Littell et al.	1 iguios appeai
İ	A2	US- 3,917,624	11-04-1975	El-Haj et al.	
	А3	US- 4,689,338	08-25-1987	John F. Gerster	
	A4	US- 4,698,348	10-06-1987	John F. Gerster	
	A5	US- 4,774,339	09-27-1988	Haugland et al.	
	A6	US- 4,929,624	05-29-1990	Gerster et al.	
	A7	US- 4,988,815	01-29-1991	Andre et al.	
	A8	US- 5,037,986	08-06-1991	John F. Gerster	
	A9	US- 5,175,296	12-29-1992	Gerster	
	A10	US- 5,187,288	02-16-1993	Kang et al.	
	A11	US- 5,238,944	08-24-1993	Wick et al.	
	A12	US- 5,248,782	09-28-1993	Haugland et al.	
\	A13	US- 5,266,575	11-30-1993	John F. Gerster	
	A14	US- 5,268,376	12-07-1993	John F. Gerster	
_	A15	US- 5,274,113	12-28-1993	Kang et al.	,
$\perp$	A16	US- 5,346,905	09-13-1994	John F. Gerster	
	A17	US- 5,352,784	10-04-1994	Nikolaides et al.	
_	A18	US- 5,367,076	11-22-1994	Gerster	
	A19	US- 5,389,640	02-14-1995	Gerster et al.	
	A20	US- 5,395,937	03-07-1995	Nikolaides et al.	
	A21	US- 5,446,153	08-29-1995	Llindstrom et al.	-
<u> </u>	A22	US- 5,482,936	01-09-1996	Kyle J. Lindstrom	
	A23	US- 5,693,811	12-02-1997	Lindstrom	
	A24	US- 5,741,908	04-21-1998	Gerster et al.	
	A25	US- 5,756,747	05-26-1998	Gerster et al.	
	A26	US- 5,939,090	08-17-1999	Beaurline et al.	
	A27	US- 6,039,969	03-21-2000	Tomai et al.	
5/4	A28	US- 6,069,149	05-30-2000	Nanba et al.	

*Examiner:	Z	Huango	

Date Considered:

8/24/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO (modified)

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Like as many sheets as necessary)

Page 2 of 4

Application Number	10/624,419
Filing Dat	July 22, 2003
First Named Inventor	Michael J. Rice
Art Unit	
Examiner Name	Unknown
Attorney Case Number	54563US011

No.	18 181		U.S. Patent	Documents	
Exam.	Cite	Document Number	Publication Date or Issue Date	Name of Patentee	Pages, Columns, Lines, Where
Init.*	No.	Doc. Number-(Kind Code if Known)	MM-DD-YYYY	or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
XH	A29	US- 6,083,505	07-04-2000	Miller et al.	
	A30	US- 6,110,929	08-29-2000	Gerster et al.	
	A31	US- 6,194,425	02-27-2001	Gerster et al.	
	A32	US- 6,245,776	06-12-2002	Skwierczynski et al.	
	A33	US- 6,331,539	12-18-2001	Crooks et al.	
_	A34	US- 6,376,669	04-23-2002	Rice et al.	
	A35	US- 2002/0055517 A1	05-09-2002	Smith	
	A36	US- 2002/0058674 A1	05-16-2002	Hedenstrom et al.	
	A37	US- 6,451,810	09-17-2002	Coleman et al.	
	A38	US- 6,518,265	02-11-2003	Kato et al.	
	A39	US- 6,525,064	02-25-2003	Dellaria et al.	
	A40	US- 6,541,485	04-01-2003	Crooks et al.	
	A41	US- 6,545,016	04-08-2003	Dellaria et al.	
	A42	US- 6,545,017	04-08-2003	Dellaria et al.	
	A43	US- 6,558,951	05-06-2003	Tomai et al.	
XV4	A44	US- 6,573,273	06-03-2003	Crooks et al	

	,		F	oreign Patent	Documents		
Exam. Cite				Publication Date	Name of Patentee or	Pages, Columns, Lines,	Translation
Init.*	No.	Ctry. Code	Number-KindCode (If known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	(Check if yes)
8/11	B1	PCT	WO 01/74343	10-11-2001			
	B2	PCT	WO 02/36592	05-10-2002			х
	В3	PCT	WO 02/46188	06-13-2002			
	B4	PCT	WO 02/46189	06-13-2002			
	B5	PCT	WO 02/46190	06-13-2002			
	В6	PCT	WO 02/46191	06-13-2002			-
	B7	PCT	WO 02/46192	06-13-2002			
	B8	PCT	WO 02/46193	06-13-2002			
XAI	B9	PCT	WO 02/46749	06-13-2002			

*Examiner:	8	Huans	Date C nsidered:	8/2/
	· U.,		Date o Tisidered.	104104

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO (modified)

#### **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

Page 3 of 4

Application Number	10/624,419
Filing Date	July 22, 2003
First Named Inventor	Michael J. Rice
Art Unit	
Examiner Name	Unknown
Attorney Case Number	54563US011

CATEN	T& THIS		F	oreign Patent	Documents		
Exam.	Cite	For	eign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation (Check if yes)
Init.*	No.	Ctry. Code	Number-KindCode (If known)	MM-DD-YYYY	Applicant of Cited Document		
SM	B10	PCT	WO 02/102377	12-27-2002			
	B11	PCT	WO 03/020889	03-13-2003			
	B12	PCT	WO 03/043572	05-30-2003			
	B13	PCT	WO 03/045391	06-05-2003			
	B14	JP	9-208584	08-12-1997			
	B15	JP	9-255926	03-26-1999			Х
	B16	JP	11-222432	08-17-1999			Х
ŀ	B17	JP	2000-247884 (abs)	09-12-2000			Х
	B18	EP	0 394 026	10-24-1990			
SN	B19	EP	1 104 764	06-06-2001			_

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS			
Exam. Init.*	Cite No.	- I with a manual transfer of the control of the co			
SH	C1	Wozniak, et al, "The Amination of 3-nitro-1, 5-naphthyridines by Liquid Ammonia/Potassium Permanganate <sup>1,2</sup> . A New and Convenient Amination Method.", <u>Journal of the Royal Netherlands Chemical Society</u> , 102, pp 511-513, December 12, 1983.			
	C2	Brennan, et al, "Automated Bioassay of Interferons in Micro-test Plates", <u>Biotechniques</u> , June/July, 78, 1983.			
	. C3	Testerman, et al., "Cytokine Induction by the Immunomodulators Imiquimod and S-27609", Journal of Leukocyte Biology, Volume 58, pp. 365-372, September 1995.			
	C4	Bachman, et al, "Synthesis of Substituted Quinolylamines. Derivatives of 4-Amino-7-Chloroquinoline", J. Org. Chem, 15, pp 1278-1284 (1950).			
	C5	Jain, et al, "Chemical and Pharmacological Investigations of Some ω-Substituted Alkylamino-3-aminopyridines", J. Med. Chem., 11, pp 87-92 (1968).			
	C6	Baranov, et al., <u>Chem. Abs.</u> 85, 94362, (1976).			
	C7	Berényi, et al, "Ring Transformation of Condensed Dihydro-as-triazines", <u>J. Heterocyclic Chem.</u> , 18, pp 1537-1540 (1981).			
	C8	Chollet, et al, "Development of a Topically Active Imiquimod Formulation", Pharmaceutical Development and Technology, 4(1), pp 35-43 (1999)			
SM	C9	Izumi, et al., "1 <i>H</i> -Imidazo[4,5- <i>c</i> ]quinoline Derivatives as Novel Potent TNF-α Suppressors: Synthesis and Structure-Activity Relationship of 1-, 2- and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i> ]pyridines", Bioorganic & Medicinal Chemistry, 11, pp 2541-2550 (2003)			

*Examiner: 2 through	Date Considered: 8/24/04
EXAMINER: Initial if reference considered, whether or not citation conformance and not considered. Include copy of this form with ne	is in conformance with MPEP 609. Draw line through citation if not in ext communication to applicant.

Substitute for form 1449A/PTO (modified)

Ap

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Lise as many sheets as necessary)

7 2 0 2033 E

Page 4 of 4

Application Number	10/624,419
Filing Date	July 22, 2003
First Named Inventor	Michael J. Rice
Art Unit	
Examiner Name	Unknown
Attorney Case Number	54563US011

DAI G		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS
Exam. Init,*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
84	C10	Gibson et al. "Cellular Requirements for Cytokine Production in Response to the Immunomodulators Imiquimod and S-27609", Journal of Interferon and Cytokine Research, 15, 537-545 (1995).

\*Examiner:

En Huary

Date Considered:

8/24/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.